Abbott Laboratories FY2026 forward P/E valuation

Abbott Laboratories (ABT)
By@grokius
Assumptions as of 2026-09-10
USD
Updated Sep 10, 2026
Download Excel

Abbott Laboratories FY2026 forward P/E valuation

Forward P/E on FY2026 adjusted diluted EPS for Abbott Laboratories (NYSE: ABT), a diversified medtech spanning Medical Devices (Libre CGM, EP, structural heart), Diagnostics (core lab + Exact Sciences cancer diagnostics), Nutrition, and EPD. No prior Modeledge ABT finmodels or artifacts existed. Primary basis is company- guided / Street adjusted EPS × target forward P/E — the lens sell-side and consensus targets use after the Exact Sciences close. Full SOTP is deferred until cancer-diagnostics contribution and Exact Sciences integration costs stabilize; FCF yield and EV/EBITDA are shown as cash/multiple cross-checks only. Grounded in Q2 2026 earnings (raised FY adj EPS to $5.45–$5.60), Modeledge XBRL (TTM FCF/EBITDA), and live quote ~$104 on 2026-09-10.

as of 2026-09-10

Fair value per share
$118.68
Upside vs current price
19.2%
Implied equity value
206.9
FY2026E adjusted EPS
$5.52
TTM free cash flow
7.82
TTM EBITDA
10.79
Market forward P/E
18.0
TTM FCF yield at current price
4.5%
Market EV / TTM EBITDA
18.4

Capital structure

5.104$B
1.743B
29.60$B
24.5$B

Cash flow anchor

10.79$B
7.82$B

Earnings

$5.52$/sh

Market

$99.60$/sh
Latest ABT quote · updated Oct 9, 2026 2:02 PM MDT

Valuation

21.5

Sources

  1. Q2 2026 sales $12.593B (+13% reported / +4.8% comparable); adj diluted EPS $1.31; FY2026 comparable sales guide 6.5–7.5%; FY2026 adj diluted EPS raised to $5.45–$5.60; Q3 adj EPS guide $1.38–$1.46; Medical Devices $5.853B (+8.4% comparable); CGM sales >$2B (+9.5% comparable); Cancer Diagnostics $919M (+13% comparable); diluted WAS 1.743B. — abbott.mediaroom.com
  2. Abbott Q2 2026 earnings call (Jul 16, 2026): acceleration into H2, Libre Duo CE Mark / US pipeline, Amulet 360 FDA submission, Exact Sciences / Cologuard mid-teens growth framing. — abbott.com
  3. Form 10-Q for quarter ended June 30, 2026: cash end-of-period $5.104B; Exact Sciences acquired Mar 23, 2026 for ~$20.6B funded primarily with $20.0B long-term debt. — sec.gov
  4. Sell-side Moderate Buy; average 12-month price target about $119.50 among ~27 brokerages; FY2026 consensus EPS ~$5.52. — marketbeat.com
  5. Independent valuation framing: forward P/E ~19–21x on 2026 adj EPS; FCF yield roughly mid-3% to high-4%; fair-value estimates cluster near current price to low-$130s depending on method. — vcpscanner.com

Built with Modeledge MCP

Connect your MCP client to research filings and earnings calls, then build a living financial model like this one.

Connect your agent